Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer

Seminars in Oncology

Volumn 30, Issue 3 SUPPL. 6, 2003, Pages 39-50

  Fernando, Nishan H ^b   Hurwitz, Herbert I ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAMPTOTHECIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; SEMAXANIB; TAXANE DERIVATIVE; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL MODEL; AREA UNDER THE CURVE; BREAST CANCER; CHILL; CLINICAL TRIAL; COLORECTAL CANCER; CROSSOVER PROCEDURE; DIARRHEA; DOSE RESPONSE; DRUG HALF LIFE; EPISTAXIS; GASTROINTESTINAL HEMORRHAGE; GLIOBLASTOMA; HEADACHE; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LEUKOPENIA; LUNG CANCER; MAJOR CLINICAL STUDY; META ANALYSIS; METASTASIS; MOUSE; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; REVIEW; RHABDOMYOSARCOMA; STOMATITIS; THROMBOSIS;

EID: 0038514919     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(03)70024-4     Document Type: Article

References (84)

1. Folkman J: Angiogenesis in cancer, rheumatoid and other disease. Nat Med 1:27-31, 1995
2. Folkman J: Angiogenic factors. Science 235:442-447, 1987
3. Garner A: Vascular diseases, in Garner AKG (ed): Pathobiology of Ocular Diseases. New York, NY, Dekker, 1994, pp 1625-1710
4. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4-6, 1990
5. Algire G, Chalkely H, Legallais F, et al: Vascular reactions of normal and malignant tumors in vivo: I. Vascular reactions of mice to wounds and to normal and neoplastic transplants. J Natl Cancer Inst 6:73-85, 1945
6. Folkman J: Tumor angiogenesis: Therapeutic implication. N Engl J Med 285:1182-1186, 1971
7. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364, 1996
8. Ferrara N: Molecular and biological properties of vascular endothelial growth factor. J Mol Med 77:527-543, 1999
9. Jain R: Barriers to drug delivery in solid tumors. Sci Am 271:58-65, 1994
10. Kerbel R: Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays 13:31-36, 1991
11. Teicher B, Sotomayor E, Huang Z, et al: Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res 52:6702-6704, 1992
12. Brower V: Tumor angiogenesis - New drugs on the block. Nat Biotechnol 17:963-968, 1999
13. Tsai J, Goldman C, Gillespie G: Vascular endothelial growth factor in human glioma cell lines: Induced secretion by EGF, PDGF-BB, bFGF. J Neurosurg 82: 864-873, 1995
14. Akagi Y, Liu W, Zebrowski B, et al: Regulation of vascular endothelial growth factor expression in human colon cancer by insulin-like growth factor-I. Cancer Res 58:4008-4014, 1998
15. Akagi Y, Liu W, Xie K, et al: Regulation of vascular endothelial growth factor expression in human colon cancer by interleukin-1 beta. Br J Cancer 80: 1506-1511, 1999
16. Cohen T, Nahari D, Cerem L, et al: Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 271:736-741, 1996
17. Potapova O, Fakhari H, Baird S, et al: Platelet-derived growth factor-B/v-sis confers a tumorigenic and metastatic phenotype to human T98G glioblastoma cells. Cancer Res 56:280-286, 1996
18. Levy A, Levy NC, Wegner S, et al: Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J Biol Chem 279:13333-13340, 1995
19. Shweiki D, Itin A, Soffer D, et al: Vascular endothelial cell growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359:843-845, 1992
20. Shweiki D, Neeman M, Itin A, et al: Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: Implication for tumor angiogenesis. Proc Natl Acad Sci U S A 92:768-772, 1995
21. Williams C, Mann M, DuBois R: The role of cyclooxygenases in inflammation, cancer and development. Oncogene 18:7908-7916, 1999
22. Tsujii M, Kawano S, Tsuiji S, et al: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cancer 93:705-716, 1998
23. Masferrer J, Leahy K, Koki A, et al: Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60:1306-1311, 2000
24. Form D, Auerbach R: PGE2 and angiogenesis. Proc Soc Exp Biol Med 172:213-218, 1983
25. Ferrara N, Henzel W: Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 161:851-858, 1989
26. Tischer E, Mitchell R, Hartman T, et al: The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 266:1459-1472, 1991
27. Park J, Keller G, Ferrara N: The vascular endothelial growth factor (VEGF) isoforms: Differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell 4:1317-1326, 1993
28. Keyt B, Berleau L, Nguyen H: The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J Biol Chem 272:7788-7795, 1996
29. Leung D, Cachianes G, Kuang WJ, et al: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246:1306-1309, 1989
30. Senger D, Galli S, Dvorak A, et al: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219:983-985, 1983
31. Dvorak H, Harvey V, Estrella P, et al: Fibrin containing gels induce angiogenesis. Implications for tumor stoma generation and wound healing. Lab Invest 57:673-686, 1987
32. Dvorak H: Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 315:1650-1659, 1986
33. Benjamin L, Hemo I, Keshet E: A plasticity window for blood vessel remodeling is defined by pericyte coverage of the preformed endothelial networks and is regulated by PDGF-B and VEGF. Development 125:1591-1598, 1998
34. Benjamin L, Golijanin D, Itin A, et al: Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 103:159-165, 1999
35. Gerber H, Dixit V, Ferrara N: Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and Al in vascular endothelial cells. J Biol Chem 273: 13313-13316, 1998
36. Goldberg M, Schneider T: Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin. J Biol Chem 269:4355-4361, 1994
37. de Vries C, Escobedo JA, Ueno H, et al: The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255:989-991, 1992
38. Terman BI, Dougher-Vermazen M, Carrion ME, et al: Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 187:1579-1586, 1992
39. Bellamy W, Richter L, Frutiger Y, et al: Expression of vascular endothelial growth factor (VEGF) and its receptors in hematopoietic malignancies. Cancer Res 59:728-733, 1999
40. Ferrer F, Miller L, Lindquist R, et al: Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology 54:567-572, 1999
41. Strizzi L, Catalano A, Vianale G, et al: Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 193:468-475, 2001
42. Shalaby F, Rossant J, Yamaguchi T, et al: Failure of blood-island formation and vasculogenesis in Flk-1 deficient mice. Nature 376:62-66, 1995
43. Fong G, Rossant J, Gertsenstein M, et al: Role of Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376:66-70, 1995
44. Pavco P, Bouhana K, Gallegos A, et al: Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors. Clin Cancer Res 6:2094-2103, 2000
45. Jeltsch M, Kaipainen A, Joukov V, et al: Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 276: 1423-1425, 1997
46. Soker S, Takashima S, Miao HQ, et al: Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92:735-745, 1998
47. Fukumura D, Xavier R, Sugiura T, et al: Tumor induction of VEGF promoter activity in stromal cells. Cell 94:715-725, 1998
48. Fox S, Giampietro G, Harris A: Angiogenesis: Pathological prognostic and growth-factor pathways and their link to trial design and anticancer drugs. Lancet Oncol 2:278-289, 2001
49. Gasparini G, Toi, M, Gion M, et al: Prognostic significance of vascular endothelial growth factor protein in nodenegative breast carcinoma. J Natl Cancer Inst 89:139-147, 1997
50. Takahashi Y, Tucker S, Kitadai Y, et al: Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. Arch Surg 132: 541-546, 1997
51. Lin P, Sankar S, Shan S: Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. Cell Growth Differ 9:49-58, 1998
52. Fairbrother W, Christinger H, Cochran A: Novel peptides selected to bind vascular endothelial growth factor target the receptor-binding site. Biochem 37:17754-17764, 1998
53. Mendel DB, Laird AD, Smolich BD, et al: Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anticancer Drug Des 15:29-41, 2000
54. Kim K, Li B, Houck K: The vascular endothelial growth factor proteins: Identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 7:53-64, 1992
55. Presto L, Chen H, O'Connor S: Humanization of anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57: 4593-4599, 1997
56. Kim K, Li B, Winner J: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 362:841-844, 1993
57. Warren R, Yaun H, Malti M: Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 95:1789-1797, 1995
58. Asano M, Ayako Y, Matsumoto T: Inhibition of tumor growth and metastasis by immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor 121. Cancer Res 55:5296-5301, 1995
59. Melnyk O, Shuman M, Kim K: Vascular endothelial growth factor promotes tumor dissemination by a mechanism distinct from its effect on primary tumor growth. Cancer Res 56:921-924, 1996
60. Borgstrom P, Bourdon M, Hillan K: Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo. Prostate 35:1-10, 1998
61. Browder T, Butterfield C, Kräling B: Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60:1878-1886, 2000
62. Nuyts R, Pels E, Greve E: The effects of 5-fluorouracil and mitomycin C on the corneal endothelium. Curr Eye Res 11:565-570, 1992
63. Belotti D, Vergani V, Drudis T, et al: The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 2:1843-1849, 1996
64. O'Leary J, Shapiro R, Ren C, et al: Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model. Clin Cancer Res 5:181-187, 1999
65. Kabbinavar F, Wong J, Ayala R, et al: The effect of antibody to vascular endothelial growth factor and cisplatin on the growth of lung tumors in nude mice. Proc Am Assoc Cancer Res 36:488, 1995 (abstr 2906)
66. Borgstom P, Gold D, Hillan K, et al: Importance of VEGF for breast cancer angiogenesis in vivo: Implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res 19:4203-4214, 1999
67. Lin Y, Nguyen C, Mendoza J: Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther 288:371-378, 1998
68. Gordon MS, Talpaz M, Margolin K, et al: Phase I trial of recombinant humanized monoclonal anti-vascular endothelial growth factor (anti-vegf mab) in patients with metastatic cancer. Proc Am Soc Clin Oncol 17:210a, 1998 (abstr 809)
69. DelProposto Z, LoRusso P, Latif Z, et al: MRI evaluation of the effects of the vascular-targeting agent ZD6126 on tumor vasculature. Proc Am Soc Clin Oncol 21:111a, 2002 (abstr 440)
70. Radema S, Beerepoot LV, Witteveen PO, et al: Clinical evaluation of the novel vascular-targeting agent, ZD6126: Assessment of toxicity and surrogate markers of vascular damage. Proc Am Soc Clin Oncol 21:110a, 2002 (abstr 439)
71. Hurwitz H, Holden SN, Eckhardt SG, et al: Clinical evaluation of ZD6474, an orally active inhibitor of VEGF signaling, in patients with solid tumors. Proc Am Soc Clin Oncol 21:82a, 2002 (abstr 325)
72. DeVore RF, Fehrenbacher L, Herbst RS, et al: A randomized phase II trial comparing rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC. Proc Am Soc Clin Oncol 19:485a, 2000 (abstr 1896)
73. Sledge G, Miller K, Novotny W, et al: A phase II trial of single-agent rhuMab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) in patients with relapsed metastatic breast cancer. Proc Am Soc Clin Oncol 19:3a, 2000 (abstr 5c)
74. Yang JC, Haworth L, Steinberg SM, et al: A randomized double-blind placebo-controlled trial of bevacizumab (anti-VEGF antibody) demonstrating a prolongation in time to progression in patients with metastatic renal cancer. Proc Am Soc Clin Oncol 21:5a, 2002 (abstr 15)
75. Bergsland EK, Hurwitz H, Fehrenbacher L, et al: A randomized phase II trial comparing rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus 5-fluorouracil/leucovorin (FU/LV) to FU/LV alone in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 19:242a, 2000 (abstr 939)
76. Bergsland EK, Fehrenbacher L, Novotny W, et al: Bevacizumab (BV) + chemotherapy (CT) may improve survival in metastatic colorectal cancer (MCRC) subjects with unfavorable prognostic indicators. Proc Am Soc Clin Oncol 20:124b, 2001 (abstr 2247)
77. Saltz L, Cox J, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343:905-914, 2000
78. Langmuir VK, Cobleigh MA, Herbst RS, et al: Successful long-term therapy with bevacizumab (Avastin) in solid tumors. Proc Am Soc Clin Oncol 21:9a, 2002 (abstr 32)
79. Kabbinavar FF, Johnson D, Langmuir VK: Patterns of tumor progression during therapy with bevacizumab (BV) and chemotherapy (CT) for metastatic colorectal cancer (MCRC) and advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 20:227a, 2001 (abstr 1105)
80. Rosen PJ, Kabbinavar F, Figlin RA: A phase I/II trial and pharmacokinetic (PK) study of SU5416 in combination with paclitaxel/carboplatin. Proc Am Soc Clin Oncol 20:98a, 2001 (abstr 389)
81. Levine M: Prevention of thrombotic disorders in cancer patients undergoing chemotherapy. Thromb Haemost 78:133-136, 1997
82. Radomski M, Moncada S: Biological role of nitric oxide in platelet function, in Moncada SHE, Berrazueta JR (eds): Clinical Relevance of Nitric Oxide in the Cardiovascular System. Madrid, Edicomplet, 1991, pp 45-56
83. Hoekman K, Kuenen B, Levi M, et al: Activation of the coagulation cascade and endothelial cell perturbation during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU5416. Proc Am Soc Clin Oncol 21:6a, 2002 (abstr 21)
84. Giantonio BJ, Levy D, Catalano PJ, et al: Incorporating angiogenesis inhibition with bevacizumab (anti-VEGF) into frontline chemotherapy with irinotecan (CPT-11), fluorouracil and leucovorin (FU/LV) for advanced colorectal cancer (advCRC): A toxicity analysis of ECOG study E2200. Proc Am Soc Clin Oncol 21:126a, 2002 (abstr 503)